FDA批准礼来的胃癌新药Cyramza

FDA批准礼来胃癌新药Cyramza --- 礼来制药公司(Eli Lilly and Company)研发的Cyramza(ramucirumab)是一种血管生成抑制剂(靶向VEGF的全人源化IgG1单抗)，其适应症为晚期胃癌或胃食管交界部腺癌。临床研究显示，Cyramza较安慰剂可更有效地改善总体生存期(5.2个月和3.8个月)，此外 Cyramza与紫杉醇(paclitaxel)联用时亦可更有效地改善生存期。常见的副作用有腹泻和高血压。

The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the region where the esophagus joins the stomach.
......

Common side effects experienced by Cyramza-treated participants during clinical testing include diarrhea and high blood pressure.

 

The FDA reviewed Cyramza under its priority review program, which provides an expedited review for drugs that have the potential, at the time the application was submitted, to be a significant improvement in safety or effectiveness in the treatment of a serious condition. Cyramza was also granted orphan product designation because it is intended to treat a rare disease or condition.

 

Cyramza is marketed by Indianapolis-based Eli Lilly.


来源: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394107.htm

--------------------------------------------------------------------------------------

附加:

乳癌患者在确诊后增加维生素C的摄入量可能有助降低死亡风险---来自EJC (《欧洲癌症杂志》) 的一篇meta分析文章显示，乳癌患者在确诊后开始服用维生素C补充剂、或增加膳食中的维生素C摄入量，可能具有降低死亡风险的作用。后者的作用更为显著。

详见 http://www.ejcancer.com/Vitamin C and survival among women with breast cancer: A Meta-analysis